ReviewTranslational breast cancer research : a journal focusing on translational research in breast cancer2026
Progress of Trop-2-targeted antibody-drug conjugates in HER-2-negative breast cancer: a mini-review.
Review in Translational breast cancer research : a journal focusing on translational research in breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) persists as a major cause of deaths associated with cancer among women globally, emphasizing the urgent need for innovative therapies. Trophoblast cell surface antigen 2 (Trop-2), a transmembrane glycoprotein involved in tumor growth, proliferation, and metastasis, has emerged as a promising therapeutic target. Trop-2-targeted antibody-drug conjugates (ADCs) improve the efficacy and reduce the safety concerns while compared to traditional chemotherapy by selectively delivering cytotoxic agents to tumor cells that express Trop-2. The expression of Trop-2 is higher in many solid tumors and is associated with poor prognosis. Various Trop-2-targeted ADCs, such as sacituzumab govitecan (SG), sacituzumab tirumotecan (SKB264), and datopotamab deruxtecan (Dato-DXd), are being actively investigated for advanced triple-negative breast cancer (TNBC) and hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC. This review discusses the clinical progress and outcomes of these Trop-2 ADCs, their potential utility in combination with immunotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors and the ongoing clinical trials, and their efficacy in the treatment of patients with brain metastases, shaping the future of Trop-2-directed cancer treatment. Overall, Trop-2-targeted ADCs were promising in treating HER2- BC, with the potential to improve patient outcomes, enhance the quality of life, and pave the way for future Trop-2-focused research. Especially, SG has shown substantial efficacy in treating both TNBC and HR+/HER2- BC, with a tolerable safety profile, and an encouraging efficacy over standard chemotherapy. Trop-2 ADCs have made significant progress in BC therapy; however, many challenges remain, which require further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.